APA (7th ed.) Citation

RM, H., K, F., M, Y., T, F., E, H., E, N., . . . J, B. (2024). Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial. Neurology, 102(5), e209137. https://doi.org/10.1212/WNL.0000000000209137

Chicago Style (17th ed.) Citation

RM, Hutchison, et al. "Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial." Neurology 102, no. 5 (2024): e209137. https://doi.org/10.1212/WNL.0000000000209137.

MLA (9th ed.) Citation

RM, Hutchison, et al. "Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial." Neurology, vol. 102, no. 5, 2024, p. e209137, https://doi.org/10.1212/WNL.0000000000209137.